BIOTAGE TURBOVAP LV EVAPORATION SYSTEM (2EA)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract award is for the procurement of two Biotage TurboVAP LV evaporation systems to enhance sample preparation workflows by enabling high-throughput, reproducible, and efficient removal of organic solvents from extracted samples. These systems are critical for concentrating analytes to consistent levels prior to instrumental analysis, thereby improving laboratory efficiency and reducing manual handling time for analysts. The equipment must deliver reliable performance under routine operational conditions to support analytical accuracy and throughput across the facility. The solicitation is identified as FDA-HFP-2026-134777-AMENDMENT1, posted on August 4, 2026, with responses due by August 10, 2026. The acquisition falls under NAICS code 334516 for laboratory analytical instrument manufacturing and is managed by the FDA Office of Acquisition and Grant Services within the Department of Health and Human Services. The office is located in Rockville, Maryland, and the equipment will be implemented at a location in Denver, Colorado. Primary point of contact for inquiries is Rodney D. Aytch, reachable via phone or email provided in the solicitation. No set-aside provisions apply, and the contract type is combined.
General Info
Agency
NAICS
Place of Performance
Denver, CO, USASet-Aside
Documents
(1)AI Contract Breakdown
Uniform Contract FormatWhat is UCF?
Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.
Timeline
Response Deadline
Organization & Contact Information
Full Description
The purpose of this procurement is to acquire two (2) solvent evaporation systems capable of high-throughput, reproducible, and efficient solvent evaporation during sample preparation. The systems shall be used to remove organic solvents from extracted samples, leaving concentrated residues for further analytical processing. The equipment shall improve laboratory efficiency,
reduce analyst handling time, and ensure consistent analyte concentration prior to instrumental analysis.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
Same awarding agency
